Merck sought leave to appeal a decision of the Federal Court of Appeal (2021 FCA 224) affirming a Federal Court decision upholding Health Canada’s refusal to add a patent relating to a formulation of Merck’s KEYTRUDA, a biologic drug containing pembrolizumab, to the Patent Register.
On May 12, 2022, the Supreme Court of Canada denied leave to Merck (Merck Canada Inc v Minister of Health, Docket No. 40043).
Should you have any questions, please do not hesitate to contact a member of the Pharmaceutical Litigation Group.
The preceding is intended as a timely update on Canadian intellectual property and technology law. The content is informational only and does not constitute legal or professional advice. To obtain such advice, please communicate with our offices directly.
Related Publications & Articles
- 
                    
Federal Court of Appeal confirms generic not required to address patent submitted before ANDS filing but listed afterOn August 8, 2025, the Federal Court of Appeal (FCA) determined that the Minister of Health’s decision to list Canadian Patent No. 2,970,315 on the Patent Register eight days after it was submitted to...Read More
- 
                    
PM(NOC) Regulations: eighth-year anniversary of major amendmentsSeptember 21, 2025, marked the eighth anniversary of the significant amendments to the Patented Medicines (Notice of Compliance) Regulations.Read More
- 
                    
Supreme Court of Canada reserves decision on appeal relating to the patentability of methods of medical treatmentToday, the Supreme Court heard oral arguments in Pharmascience Inc v Janssen Inc (Supreme Court File No 41209) and reserved its decision.Read More
